Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Crescita Therapeutics Inc
PureTech Health plc - American Depositary Shares
Sibannac Inc
Star Alliance International Corp
WisdomTree Bitcoin Fund
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares
(NQ:
LSE
)
4.360
-0.070 (-1.58%)
Delayed Quote
Updated: 11:29 AM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
November 04, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Sintana Energy to Present at the Oil & Gas Virtual Investor Conference November 5th
November 04, 2026
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
PPHC Announces New $105 Million Senior Secured Credit Facility
November 02, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
PPHC Announces Acquisition of Reevemark
November 02, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
November 01, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
October 28, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
PPHC to Report Third Quarter 2026 Financial Results and Participate in Upcoming Investor Conference
October 28, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
Ahead of a January 2027 Pentagon Sourcing Rule, Tungsten Projects Outside China Move Into Permits and Restarts
October 27, 2026
News Provided by Equity Insider on behalf of Western Star Resources Inc.
From
Equity Insider
Via
GlobeNewswire
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
October 26, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
October 26, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
October 26, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
October 25, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
October 23, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
October 20, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Seeing Machines launches Technical Paper demonstrating real-time 3D human understanding for Physical AI
September 30, 2026
Delivering up to 180 FPS on NVIDIA Jetson Thor, Seeing Machines HMR combines state-of-the-art accuracy with low latency and compact model size for embedded deployment
From
Seeing Machines
Via
GlobeNewswire
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
September 30, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
September 28, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
September 27, 2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
September 25, 2026
From
Avacta Group PLC
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
September 23, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
The Elmet Group Secures Long-Term Tungsten Offtake Agreement with Tungsten West’s Hemerdon Mine
September 22, 2026
From
The Elmet Group
Via
GlobeNewswire
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
September 16, 2026
From
Avacta Group PLC
Via
GlobeNewswire
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
September 14, 2026
From
Avacta Group PLC
Via
GlobeNewswire
PPHC Increases 2026 Interim Dividend to $0.117 Per Share
September 11, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
September 03, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
August 27, 2026
Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
August 16, 2026
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Public Policy Holding Company, Inc. Announces Q2 2026 Financial Results
August 10, 2026
From
Public Policy Holding Company, Inc.
Via
GlobeNewswire
TierPoint Launches Adapt DDoS Protection
August 04, 2026
Always-On, Low-Latency DDoS Protection Powered by Corero Technology
From
TierPoint
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
